Plerixafor is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1-alpha). This agent was approved on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkins lymphoma (NHL) and multiple myeloma (MM). Selective CXCR4 antagonist. Melting Point: As Reported Solubility: As Reported Method for Determining Identity: Proton NMR (CD3OD) Spectroscopic and Mass Spectrometric Analysis TLC Conditions: As Reported Elemental Analysis: As Reported Storage and Stability: May be stored at RT for short-term only. Long-term storage is recommended at 4C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.
Molecular Weight:
502.78
Purity:
~90%
CAS Number:
[110078-46-1]
* VAT and and shipping costs not included. Errors and price changes excepted
